The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website: https://www.poolbegpharma.com/
The Annual General Meeting will be held at the offices of
Contact:
Tel: +44 (0) 207 183 1499
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 207 408 4090
Email: poolbeg@optimumcomms.com
About
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the
Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
(C) 2024 Electronic News Publishing, source